Status:
UNKNOWN
Hippocampus Avoidance During Intensity Modulated Radiotherapy for T4 Nasopharyngeal Carcinoma Patients
Lead Sponsor:
Zhejiang Cancer Hospital
Conditions:
Nasopharyngeal Carcinoma
Eligibility:
All Genders
18-75 years
Brief Summary
This is a prospective, non-randomized phase III study observing the cognitive function changes with conformal hippocampus avoidance during intensity modulated radiotherapy for T4 nasopharyngeal carcin...
Detailed Description
All patients received intensity modulated radiotherapy or Tomotherapy with or without chemotherapy. Before radiotherapy, the patients will receive brain MRI scanning and the brain MRI images will be f...
Eligibility Criteria
Inclusion
- Histologically or cytologic confirmed nasopharyngeal carcinoma
- ECOG performance scale 0-2
- Tumor stage is T4N0-3M0-1 according to 8th American Joint Commission on Cancer edition
- Adequate hepatic, renal and hematologic functions (hemoglobin ≥ 90g/L, platelets ≥ 100×10\^9/L, neutrophils ≥ 1.5×10\^9/L, serum transaminase \< 2.5×the upper limit of normal(ULN), (If liver metastases, serum transaminase\< 5×the ULN), creatinine clearance rate \> 60ml/min.
- Informed consent signed.
Exclusion
- History of malignant tumors.
- Any severe complications contraindicated chemotherapy or radiotherapy.
- Medical history of central nervous system, cognitive or psychological diseases;
- Pregnant or nursing women.
- Patients with mental disease cannot complete the questionaire.
- MRI contraindication -
Key Trial Info
Start Date :
January 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 1 2022
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT03411954
Start Date
January 1 2018
End Date
March 1 2022
Last Update
January 26 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China, 310022